Table 1.

Clinico-pathologic data of 145 GIST patients included into this study

FactorNumber of cases5 Years disease-free survival rate ± SE5 years overall survival rate ± SE
LocalizationP < 0.001aP > 0.05
 Gastric94 (64.8%)89.8 ± 4.3%
 Duodenum6 (4.1%)100%
 Small intestine27 (18.6%)62.2 ± 10.1%
 Rectum3 (2.1%)100%
 Other15 (10.3%)45.1 ± 14.9%
Risk FletcherP = 0.001aP < 0.001a
 Very low16 (11%)87.5 ± 11.7%100%
 Low50 (34.5%)93.9 ± 4.2%95.5 ± 4.4%
 Intermediate32 (22.1%)79 ± 8.6%96.4 ± 3.5%
 High47 (32.4%)54.8 ± 9.7%73.8 ± 7.8%
Risk MiettinenP < 0.001aP < 0.001a
 None18 (12.4%)90 ± 9.5%100%
 Very low38 (26.2%)96.3 ± 3.6%93.8 ± 6.1%
 Low28 (19.3%)77 ± 10.7%95.8 ± 4.1%
 Moderate17 (11.7%)84.6 ± 10%100%
 High29 (20%)59.9 ± 12.4%65.5 ± 9.7%
 Insufficient data15 (10.3%)45.1 ± 14.9%83.3 ± 15.2%
Staging UICCP < 0.00aP > 0.05
 pT119 (13.1%)90 ± 9.5%
 pT265 (44.8%)84.5 ± 6.2%
 pT340 (27.6%)73.6 ± 8.9%
 pT421 (14.5%)50.5 ± 12.9%
Mitotic rate UICCP = 0.001aP < 0.001a
 Low96 (66.2%)87.1 ± 4.5%96.7 ± 2.4%
 High49 (33.8%)58.9 ± 8.9%75.8 ± 7.1%
Synchronous metastasesP = 0.003aP < 0.001a
 No131 (90.3%)80.7 ± 4.3%94.6 ± 2.7%
 Yes14 (9.7%)47.3 ± 19%51.3 ± 12.5%
KIT mutationP > 0.05P > 0.05
 No53 (36.6%)
 Yes92 (63.4%)
PDGFRA mutationP > 0.05P > 0.05
 No124 (85.5%)
 Yes21 (14.5%)
  • aSignificant results after FDR adjustment.